positive

Anaveon Announces Presentation of Positive ANV600 Clinical Data at ASCO 2026 and Actively Seeks Partners for its Legacy Oncology Portfolio

BASEL, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage preclinical biotechnology company focused on reprogramming the immune system…

1 day ago

Berlin Heals Presents Positive Late Breaking Results from the CMIC-III First-In-Human Less Invasive Study

High Impact Session presented at Heart Rhythm Society's Congress in ChicagoFirst time showing results of new Less Invasive approachImprovement in…

3 weeks ago

New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

March 28, 2026 15:00 ET  | Source: Roivant Sciences The results of the Phase 3 VALOR trial were published in…

1 month ago

Crescel Reports Positive Randomized Controlled Trial Results for Biobotanical Skin Renewal Cream in Rosacea

Study Shows Greater Clinical Improvement vs. Metronidazole-Based Standard of Care with Favorable TolerabilityMIAMI BEACH, Fla., March 20, 2026 /PRNewswire/ -- Crescel LLC,…

2 months ago

Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcytes 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

March 18, 2026 19:34 ET  | Source: Vaxcyte, Inc. Based on the Strength of Unprecedented Results from the Positive Phase…

2 months ago

First Ever Real-World Evidence of Eversense 365 Presented at ATTD Demonstrates Sustained Performance and Positive Impact Throughout One-Year of Wear

March 14, 2026 10:15 ET  | Source: Senseonics Holdings, Inc. New data shows positive real-world impact of the world’s first…

2 months ago

Aster DM Healthcare receives overwhelmingly positive shareholder and creditors vote for Aster-QCIL merger

The transaction had received CCI and Stock Exchange approvals earlier.The combined entity Aster DM Quality Care Ltd will become one…

2 months ago

Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity

-- -18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142) at 52 weeks, including 12 Japanese patients and…

2 months ago